Immatics Biotechnologies Gmbh

Heiko Schuster

Jens Fritsche

Oliver Schoor

Daniel Johannes Kowalewski

Toni Weinschenk

Chih-Chiang Tsou

Franziska Hoffgaard

Harpreet Singh

Colette Song

Hans-Georg Rammensee

Janet Peper

Philipp Wagner

Michael Roemer

Annika Sonntag

Jens Hukelmann

Linus Backert

Kevin Roehle

Gisela Schimmack

Ricarda Hannen

Florian Koehler

Christoph Schraeder

Claudia Wagner

Dominik Maurer

Sebastian Bunk

Felix Unverdorben

Martin Hofmann

Meike Hutt

Gabriele Pszolla

Frank Schwoebel

Sara Yousef

Lena Wullkopf

Phillipp Wagner

Kevin Röhle

Maike Jaworski

Florian Schwoerer

Phillip Wagner

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Peptides displayed by HLA for use in immunotherapy against different types of cancers

Peptides displayed by HLA for use immunotherapy against different types of cancers

The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Antigen binding proteins specifically binding MAGE-A

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods

Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods

Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods

B*44 restricted peptides for use in immunotherapy against cancers and related methods

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

A*03 restricted peptides for use in immunotherapy against cancers and related methods

Growing community of inventors

Tuebingen, Germany

Heiko Schuster